首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1122409

抗生素市場：按藥物類別、分銷渠道和地區 - 規模、份額、前景和機會分析，2022-2030

Antibacterial Drugs Market, by Drug Class, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年08月16日 | 出版商:

Coherent Market Insights | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

抗菌劑來源於細菌和真菌。這些抗菌劑由簡單的分子合成，形成複雜的分子。抗生素通過抑制細胞壁形成、增加細胞膜通透性、抑制細胞壁形成、核酸代謝等代謝過程等多種方式來抑制蛋白質合成、核酸代謝等代謝過程。抗生素可以通過增加或減少其代謝來增加或減少其他藥物的血清濃度。臨床上最相關的相互作用涉及治療率低的藥物。其他藥物也可能提高或降低抗生素水平。抗生素包括苯氧甲基青黴素、青黴素 V 和其他用於治療由細菌引起的疾病的強效藥物。抗生素不能治愈病毒感染，例如感冒、流感和大多數咳嗽。

市場動態

預計市場參與者之間的合作夥伴關係等無機活動的增加將在預測期內推動全球抗菌藥物市場的增長。例如，2021 年 3 月，Cipla Limited 的附屬公司 Cipla USA Inc. 的子公司 Cipla Therapeutics 和專注於健康安全市場的商業階段製藥公司 SIGA Technologies, Inc. 宣布，他們將，除其他外，TB. 宣布了戰略合作夥伴關係，以提供持續創新和獲得針對生物威脅的新型抗菌劑。

此外，專業製藥公司 R-Pharm Group 於 2017 年 4 月與日本綜合貿易公司 Mitsui & Co., Ltd. 建立戰略合作夥伴關係，後者收購了 R-Pharm Group 約 10% 的股份。宣布已經結束。這一合作夥伴關係將使 R-Pharm 集團能夠擴大其在日本的業務存在。

本研究的主要特點

本報告對全球抗菌藥物市場進行了詳細分析，以 2021 年為基準年，預測了預測期（2022-2030 年）的市場規模（百萬美元）和復合年增長率（CAGR%）。 .
解釋不同細分市場的潛在收入機會，並描述該市場具有吸引力的投資建議矩陣。
它還提供了有關市場驅動因素、限制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
根據公司亮點、產品組合、關鍵亮點、業績和戰略等參數，展示了全球抗菌藥物市場主要參與者的概況。
本研究涵蓋的主要公司包括 Spero Therapeutics, Allecra Therapeutics, R-Pharm Group, Melinta Therapeutics LLC, MicuRx, TenNor Therapeutics Ltd, Venatorx Pharmaceuticals, Inc., GlaxoSmithKline plc., AstraZeneca , Bayer AG , Johnson & Johnson, Bristol-Myers Squibb Company, Merck & Co., Inc., Eli Lilly and Company, AbbVie Inc., Novartis AG, Pfizer Inc., 和 Sanofi
本報告中的見解將使企業營銷人員和高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。我猜。
The Global Antibacterial Drugs Market 報告針對行業中的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和財務分析師。
利益相關者可以通過用於分析全球抗菌藥物市場的各種戰略矩陣來促進決策制定。

內容

第 1 章目的和先決條件

調查目的
先決條件
縮寫說明

第二章市場展望

舉報內容
- 市場定義和範圍
執行摘要
- 市場快照：按藥物類別
- 市場快照：按分銷渠道
- 市場概況：按地區劃分
連貫的機會圖 (COM)

第 3 章市場動態、法規和趨勢分析

市場動態
- 驅動程序
- 限制因素
- 商機
影響分析
主要發展狀況
行業趨勢
監管場景
最近的產品批准/發布
PEST 分析
搬運工分析

第 4 章全球抗生素市場 - 冠狀病毒 (COVID-19) 大流行的影響

對需求的影響
對醫療保健的影響
流行病學

第 5 章全球抗生素市場，按藥物類別，2017-2030 年

B-內□胺系統
奎諾酮類
大環內酯類
四環素類
氨基糖甘類
磺胺類系統
苯酚
其他

第 6 章。2017-2030 年全球抗菌藥物市場，按分銷渠道分列

醫院藥房
零售藥房
在線藥店

第 7 章。2017-2030 年按地區分列的全球抗菌藥物市場

北美
美國
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地區
歐洲
德國
英國
法國
意大利
西班牙
俄羅斯
其他歐洲地區
亞太地區
中國
印度
日本
澳大利亞
韓國
東盟
其他亞太地區
中東
海合會
以色列
其他中東
非洲
南非
中非
北非

第 8 章競爭格局

熱圖分析
市場份額分析
- Spero Therapeutics
- Allecra Therapeutics
- R-Pharm Group
- Melinta Therapeutics LLC
- MicuRx
- TenNor Therapeutics Ltd
- Venatorx Pharmaceuticals, Inc.
- GlaxoSmithKline plc.
- AstraZeneca
- Bayer AG
- Johnson & Johnson
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
- Eli Lilly and Company
- AbbVie Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi

第九章章節

調查方法介紹
關於出版商

簡介目錄

Product Code: CMI177

Antibacterial drugs are derived from bacteria or molds. These antibacterial drugs are synthesized from simple molecules to form complex molecules. Antibiotics work in a variety of ways, such as inhibiting cell wall production, increasing cell membrane permeability, and interfering with protein synthesis, nucleic acid metabolism, and other metabolic processes by inhibiting cell wall production, nucleic acid metabolism, and other metabolic processes. Antibiotics can raise or lower the serum levels of other medications by increasing or decreasing their metabolism. The most clinically important interactions involve drugs with a low therapeutic ratio. Other drugs can also increase or decrease levels of antibiotics. Antibacterial drugs include a range of powerful drugs such as phenoxymethylpenicillin, penicillin V. and are used to treat diseases caused by bacteria. Antibiotics cannot treat viral infections, such as cold, flu, and most coughs.

Market Dynamics

Increasing inorganic activities such as partnerships among market players is expected to drive the global antibacterial drugs market growth over the forecast period. For instance, In March 2021, Cipla Therapeutics, a division of Cipla USA Inc., an affiliate of Cipla Limited, and SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on health security market announced a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly against bio threats such as tuberculosis and others.

Furthermore, In April 2017, R-Pharm Group, a specialty pharmaceutical company had announced that it entered into a strategic partnership with Mitsui & Co., Ltd., a Japan-based general trading company which acquired around 10% of R-Pharm Group's shares. This partnership would help R-Pharm Group expand its business presence in Japan

Key features of the study:

This report provides an in-depth analysis of the Global Antibacterial Drugs Market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global antibacterial drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, strategies
Key companies covered as a part of this study include Spero Therapeutics, Allecra Therapeutics, R-Pharm Group, Melinta Therapeutics LLC, MicuRx, TenNor Therapeutics Ltd, Venatorx Pharmaceuticals, Inc., GlaxoSmithKline plc., AstraZeneca , Bayer AG , Johnson & Johnson, Bristol-Myers Squibb Company, Merck & Co., Inc., Eli Lilly and Company, AbbVie Inc., Novartis AG, Pfizer Inc., and Sanofi
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The Global Antibacterial Drugs Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the Global Antibacterial Drugs Market

Detailed Segmentation:

Global Antibacterial Drugs Market, by Drug Class:
- B-lactams
- Quinolones
- Macrolides
- Tetracyclines
- Aminoglycosides
- Sulfonamides
- Phenicols
- Others
Global Antibacterial Drugs Market, by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Antibacterial Drugs Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
  - By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Region:
- South Africa
- Central Africa
- North Africa
Company Profiles
- Spero Therapeutics *
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Allecra Therapeutics
- R-Pharm Group
- Melinta Therapeutics LLC
- MicuRx,
- TenNor Therapeutics Ltd
- Venatorx Pharmaceuticals, Inc.
- GlaxoSmithKline plc.
- AstraZeneca
- Bayer AG
- Johnson & Johnson
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
- Eli Lilly and Company
- AbbVie Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunity
Impact Analysis
Key Developments
Industry Trends
Regulatory Scenario
Recent Product Approval/Launches
PEST Analysis
Porter's Analysis

4. Global Antibacterial Drugs Market- Impact of Coronavirus (COVID-19) Pandemic

Impact on Demand
Impact on Healthcare
Epidemiology

5. Global Antibacterial Drugs Market, By Drug Class, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
B-lactams
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Quinolones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)
Macrolides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Tetracyclines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)
Aminoglycosides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Sulfonamides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)
Phenicols
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)

6. Global Antibacterial Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)

7. Global Antibacterial Drugs Market, By Region, 2017 - 2030 (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2030(%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2030
- Regional Trends
North America
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
U.S.
Canada
Latin America
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Region/Country, 2017 - 2030 (US$ Mn)
South Africa
Central Africa
North Africa